Ribo Life Science

Suzhou, China · Founded 2007 · Publicly Held

Developer and provider of RNA interference ( RNAi ) technology designed to treat liver diseases. Ribo Life Science is based in Suzhou, China and was founded in 2007. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.2 billion (Jan 2026). It has raised $285 million.

Last price · $/share
—
Implied valuation
$1.2B
Total raised
$285.3M
Last round
—

Who backs Ribo Life Science?

12 investors
InvestorType
CICC CapitalPE / buyout
Kunshan Hi-tech Venture CapitalOther
China Asset Management CompanyAsset manager
Springs CapitalGrowth equity
Ivyrock Asset ManagementHedge fund
Arc Avenue Asset Management—
CR Life Sciences—
Dacheng Fund—
Erik Selin Fastigheter—
Huatai Capital—
+ 2 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Ribo Life Science investors

12 investors are on record for Ribo Life Science, including CICC Capital, Kunshan Hi-tech Venture Capital, China Asset Management Company and Springs Capital.

Free account
More of Ribo Life Science with a free account
  • ·The complete investor list: 12 names
  • ·Watch Ribo Life Science: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 12 firms already write checks for companies like Ribo Life Science. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View